Previous Close | 35.73 |
Open | 35.99 |
Bid | 35.03 x 4000 |
Ask | 36.26 x 3200 |
Day's Range | 35.26 - 36.15 |
52 Week Range | 32.96 - 47.89 |
Volume | |
Avg. Volume | 6,183,001 |
Market Cap | 73.273B |
Beta (5Y Monthly) | 0.18 |
PE Ratio (TTM) | 12.96 |
EPS (TTM) | 2.78 |
Earnings Date | Feb 01, 2017 - Feb 06, 2017 |
Forward Dividend & Yield | 2.48 (6.90%) |
Ex-Dividend Date | May 19, 2022 |
1y Target Est | 56.81 |
Yahoo Finance health care reporter Anjalee Khemlani looks at which pharmaceutical stocks are being affected by litigation surrounding alleged carcinogenic materials in Zantac derivatives.
The FTSE 100 pharmaceutical giant's share price suffered its biggest drop since 1998 on Thursday.
The pharma giant hit back at allegations that the use of Zantac, known chemically as ranitidine, increases the risk of cancer.